Pharmacokinetic and mass balance study of unlabelled and 14C-labelled emedastine difumarate in healthy volunteers

Xenobiotica

Volumn 32, Issue 9, 2002, Pages 761-770

  Brunner, M ^a   Kletter, K ^b   Assandri, A ^b   Ermanno Corrado, M ^b   Eichler, H G ^b   Muller M ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; EMEDASTINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG FECES LEVEL; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; NORMAL HUMAN; RADIOACTIVITY; SEX DIFFERENCE; URINARY EXCRETION;

ADULT; AREA UNDER CURVE; BENZIMIDAZOLES; CARBON RADIOISOTOPES; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; KIDNEY; MALE; MODELS, CHEMICAL; TIME FACTORS;

EID: 0036746732     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250210143001     Document Type: Article

References (17)

1. Amada, T. and Awata, N., 1990, Metabolism of a new antiallergic agent, emedastine difumarate, in human. Xenobiotics Metabolism and Disposition, 5, 871-881.
2. 14C] KB-2413). Journal of Labelled Compounds and Radiopharmaceuticals, 24, 331-338.
3. Fukuda, T., Morimoto, Y., Iemura, R., Kawashima, T., Tsukamoto, G. and Ito, K., 1984b, Effect of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)-benzimidazole (KB-2413), a new antiallergic, on chemical mediators. Arzneimittelforschung, 34, 801-805.
4. Fukuda, T., Saito, T., Tajima, S., Shimohara, K. and Ito, K., 1984a, Antiallergic effect of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate (KB-2413). Arzneimittelforschung, 34, 805-810.
5. Hamada, T., Kadowaki, M. and Awata, N., 1987, Radioreceptor assay for a new antiallergic agent, 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate (KB-2413), in plasma. Chemical and Pharmaceutical Bulletin (Tokyo), 35, 3329-3335.
6. Herranz, U., Rusca, A. and Assandri, A., 2001, Emedastine-ketoconazole: pharmacokinetic and pharmacodynamic interactions in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics, 39, 102-109.
7. 1-receptor antagonist emedastine in healthy volunteers. European Journal of Clinical Pharmacology, 55, 837-841.
8. Joukhadar, C., Herranz, U., Pernerstorfer, T., Assandri, A., Klein, N., Schrolnberger, C., Lackner, E., Eichler, H. G. and Müller, M., 2001, Pharmacokinetics of emedastine difumarate, a new anti-histaminic agent in patients with renal impairment. European Journal of Clinical Pharmacology, 56, 905-910.
9. Nakajima, S., Tsutani, Y., Ohishi, M., Doi, Y., Yamazaki, K. and Ohba, Y., 1989, Phase I study on emedastine difumarate (KG-2413). Single and consecutive administration with KG-2413 tablets. Kiso to Rinsho, 23, 5419-5430.
10. Saito, T., Fukuda, T., Sukamoto, T., Yoshidomi, M., Morimoto, Y., Shimohara, K. and Ito, K., 1988a, General pharmacology of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate. 1st Communication: Effects on the central nervous system. Arzneimittelforschung, 38, 66-69.
11. Saito, T., Fukuda, T., Tajima, S., Sukamoto, T., Yamashita, A., Kanazawa, T., Morimoto, Y., Shimohara, K., Nishimura, N., Yokota, K. et al. 1988b, General pharmacology of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl) benzimidazole difumarate. 2nd Communication: Effects on the circulation and the other systems. Arzneimittelforschung, 38, 267-272.
12. Saito, T., Nishimura, N., Tajima, S., Fukuda, T. and Ito, K., 1987, Anti-allergic effects of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole fumarate (KB-2413). Nippon Yakurigaku Zasshi, 89, 55-62.
13. Sakai, T., 1987, The biological fate of emedastine difumarate. Absorption and excretion after oral administration to rats and guinea pigs. Xenobiotics Metabolism and Disposition, 2, 123-131.
14. Slater, J. W., Zechnich, A. D. and Haxby, D. G., 1999, Second-generation antihistamines: a comparative review. Drugs, 57, 31-47.
15. I-blockers on neuropharmacological and behavioral effects including 1-(2-ethoxethyl)-2-(4-methyl-1-homopiperazinyl) benzimidazole difumarate (KB-2413), a new antiallergic agent. Archives of International Pharmacodynamics, 280, 275-291.
16. Wada, Y., 1989, Absorption, metabolism and excretion of an antiallergic agent, emedastine difumarate, in dogs. Xenobiotics Metabolism and Disposition, 4, 471-480.
17. Wada, Y., Hamada, T., Kawashima, T. and Awata, N., 1990, In vitro metabolism of an antiallergic agent, emedastine difumarate, in rats and guinea pigs. Yakugaku Zasshi, 10, 40-48.